HC Wainwright Issues Positive Estimate for JSPR Earnings

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Investment analysts at HC Wainwright increased their Q1 2026 EPS estimates for shares of Jasper Therapeutics in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.37) for the quarter, up from their previous estimate of ($0.79). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share. HC Wainwright also issued estimates for Jasper Therapeutics’ Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.71) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($1.09) EPS, FY2028 earnings at ($0.85) EPS and FY2029 earnings at ($0.78) EPS.

Several other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Thursday, January 22nd. Rodman & Renshaw assumed coverage on Jasper Therapeutics in a research report on Tuesday, January 13th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, UBS Group assumed coverage on Jasper Therapeutics in a research note on Monday, March 23rd. They set a “neutral” rating for the company. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Jasper Therapeutics has an average rating of “Hold” and a consensus price target of $19.88.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $0.69 on Thursday. The stock has a market capitalization of $19.25 million, a P/E ratio of -0.15 and a beta of 3.20. The stock’s 50-day moving average price is $1.27 and its 200-day moving average price is $1.74. Jasper Therapeutics has a 12-month low of $0.69 and a 12-month high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.47.

Institutional Investors Weigh In On Jasper Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of JSPR. Engineers Gate Manager LP purchased a new position in shares of Jasper Therapeutics during the fourth quarter valued at approximately $26,000. Panagora Asset Management Inc. purchased a new stake in Jasper Therapeutics in the fourth quarter worth $35,000. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics in the first quarter valued at $46,000. Voleon Capital Management LP purchased a new position in Jasper Therapeutics during the 3rd quarter valued at $50,000. Finally, Marex Group plc purchased a new position in Jasper Therapeutics during the 2nd quarter valued at $74,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.